Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SERENA-6 early switch to camizestrant in ESR1-mutant HR-positive/HER2-negative metastatic breast cancer
MOH_2023-06-11_012725Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of camizestrant in breast cancer (2 arms), sponsored by AstraZeneca. Primary endpoint: Progression-free survival. Started May 2023; status: recruiting.
02
Drugs
camizestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2023-06-11_012725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-06-11_012725.